Chemotherapy for Large-Cell Lymphoma: Optimism and Caution

Editorials1 July 1985Chemotherapy for Large-Cell Lymphoma: Optimism and CautionMORTON COLEMAN, M.D.MORTON COLEMAN, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-103-1-140 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe treatment of large-cell lymphoma is proving to be an exciting page in the unfolding story of cancer chemotherapy. Excitement and optimism are generated by the realization that many of the principles and theories developed in stepwise fashion for cancer chemotherapy may actually be working in the clinic, at least for this tumor. The results achieved in the study reported by Klimo and Connors in the May issue (1) herald the eventuality of cure for almost all patients with large-cell lymphoma, a disease that was usually fatal 15 years ago (2). Of 61 patients treated with the combination chemotherapy regimen...References1. KLIMOCONNORS PJ. MACOP-B chemotherapy for the treatment of advanced diffuse large-cell lymphoma. Ann Intern Med. 1985;102:596-602. LinkGoogle Scholar2. PASMANTIERCOLEMANSILVER MMR. Chemotherapy of the non-Hodgkin's lymphomas. Med Clin North Am. 1976;60:1043-52. CrossrefMedlineGoogle Scholar3. COLEMANBOYDBERNHARDT MDB. COPBLAM III: combination chemotherapy for diffuse large cell lymphoma with cyclophosphamide, infusional Oncovin, prednisone, infusional bleomycin, Adriamycin and Matulane [Abstract]. Proc Am Soc Clin Oncol. 1984;3:C-964. Google Scholar4. FISHERDEVITAHUBBARD RVS. Radomized trial of ProMACE-MOPP vs ProMACE CytaBOM in previously untreated, advanced stage, diffuse aggressive lymphoma [Abstract]. Proc Am Soc Clin Oncol. 1984;3:C-945. Google Scholar5. DABICHENSMINGERLIEPMANZUCKERMANWHEELERLOBUGLIO LWMKRA. Intensive chemotherapeutic approach to the treatment of large cell (histiocytic) lymphoma: update [Abstract]. Proc Am Soc Clin Oncol. 1984;3:C-969. Google Scholar6. FREI E. Progress against lymphoma. In: HOLLAND JF, THOMAS ED, FREEMAN AI, FREI E III, FREIREICH EJ, ARLIN ZA, eds. Progress and Controversies in Leukemia and Lymphoma. New York: Audio Visual Medical Marketing, Inc. ; 1983:40-47. Google Scholar7. ROBINSAUBUCHONHAFEZBOZDECHSTEEVESDAVIS HJGMRT. Late recurrences of histiocytic lymphoma after treatment. Cancer. 1984;53:2663-7. CrossrefMedlineGoogle Scholar8. DEVITASIMONHUBBARD VRS. Curability of advanced Hodgkin's disease with chemotherapy: long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med. 1980;92:587-95. LinkGoogle Scholar9. DEVITACANELLOSCHABNERSCHEINHUBBARDYOUNG VGBPSR. Advanced diffuse histocytic lymphoma, a potentially curable disease: results with combination chemotherapy. Lancet. 1975;1:248-50. CrossrefMedlineGoogle Scholar10. GOLDIECOLDMANGUDAUSKAS JAG. Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat Rep. 1982;66:439-49. MedlineGoogle Scholar11. NORTONSIMON LR. Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat Rep. 1977;61:1307-17. MedlineGoogle Scholar12. FISHERDEVITAHUBBARD RVS. Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of ProMACE and MOPP chemotherapy. Ann Intern Med. 1983;98:304-9. LinkGoogle Scholar13. SKARINCANELLOSROSENTHAL AGD. Improved prognosis of diffuse histocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD). J Clin Oncol. 1983;1:91-8. CrossrefMedlineGoogle Scholar14. LAURENCECOLEMANALLENSILVERPASMANTIER JMSRM. Combination chemotherapy of advanced diffuse histiocytic lymphoma with the six-drug COP-BLAM regimen. Ann Intern Med. 1982;97:190-5. LinkGoogle Scholar15. CARDEMACKINTOSHROSENBERG PFS. A dose and time response analysis of the treatment of Hodgkin's disease with MOPP chemotherapy. J Clin Oncol. 1983;2:146-53. CrossrefGoogle Scholar16. TURMANCOLEMANSILVERPASMANTIER SMRM. High dose methotrexate with citrovorium factor in adult lymphoma. Cancer. 1977;40:2823-8. CrossrefMedlineGoogle Scholar17. JAGANNATHVELASQUEZTUCKERMANNINGMCLAUGHLINFULLER SWSJPL. Stage IV diffuse large-cell lymphoma: a long-term analysis. J Clin Oncol. 1985;3:39-47. CrossrefMedlineGoogle Scholar18. ARMITAGEHUTCHINSMORAVEC JMD. Intensive 6-drug combination chemotherapy for diffuse aggressive lymphoma [Abstract]. Proc Am Soc Clin Oncol. 1984;3:C-953. Google Scholar19. GULATISHANKSTRAUS SBD. Autologous stem cell transplantation for poor prognosis lymphoma [Abstract]. Proc Am Soc Clin Oncol. 1984;3:C-958. Google Scholar20. HOLLISTERSILVERGORDONCOLEMAN DRBM. Continuous infusion vincristine and bleomycin with high dose methotrexate for resistant non-Hodgkin's lymphoma. Cancer. 1982;50:1690-4. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: MORTON COLEMAN, M.D.Affiliations: New York Hospital-Cornell Medical Center New York, New York PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byOptimizing treatment combination for lymphoma using an optimization heuristicIntensified 12-week CHOP (I-CHOP) plus G-CSF compared with standard 24-week CHOP (CHOP-21) for patients with intermediate-risk aggressive non-Hodgkin lymphoma: a phase 3 trial of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON)Non-hodgkin's lymphoma of unfavourable histology: A multivariate analysis of factors predicting the response to chopToxicity and preliminary results with a new eight-drug regimen (CEOP-IMVP-DEXA) in the treatment of aggressive lymphomasP-CHOP: Cisplatin (P) Added to the Standard CHOP Regimen as First-Line Treatment for Aggressive Non-Hodgkin LymphomaAdding high-dose tamoxifen to CHOP does not influence response or survival in aggressive non-Hodgkin's lymphoma: an interim analysis of a randomized phase III trialAugmented therapy of extensive hodgkin’s disease: radiation to known disease or prolongation of induction chemotherapy did not improve survival—results of a cancer and leukemia group B studyBone marrow involvement, in intensively treated patients with intermediate grade non-hodgkin's lymphoma, is a risk factor for granulocytopenia and feverMobilization of Peripheral Blood Progenitor Cells Following CHOP Treatment Combined with Delayed Granulocyte Colony-Stimulating Factor Administration in Patients with Non-Hodgkin's LymphomaCombined chemotherapy and radiotherapy in diffuse large cell immunoblastic lymphoma: A phase II study of CHOP/bleomycin/methotrexate alternating with ifosfamide/methotrexate/etoposideMACOP-B vs F-MACHOP Regimen in the Treatment of High-Grade Non-Hodgkin's LymphomasEfficacy of Delayed Granulocyte Colony-Stimulating Factor after Full Dose CHOP Therapy in Non-Hodgkin's Lymphoma: A Pilot Study for a Leukocyte Count Oriented RegimenPhase III Comparative Trial Uisng CHOP vs CIOP in the Treatment of Advanced Intermediate-Grade Non-Hodgkin's LymphomaTreatment of aggressive non-hodgkin's lymphomas: Lessons from the past 10 yearsCT of primary colonic lymphomaThe Response of Diffuse Large Cell and Other Intermediate Grade Non-Hodgkin's Lvmphomas to Adriamvcin Containinr Combination ChemotherapyComparison of a Standard Regimen (CHOP) with Three Intensive Chemotherapy Regimens for Advanced Non-Hodgkin's LymphomaPrimary malignant lymphoma of the uterus: localization in a cervical polypTreatment of diffuse large-cell lymphoma: A summary of outcome for patients treated by the Southwest Oncology GroupCOP-BLAM Multidrug Infusion Chemotherapies for Lymphoma: Results in a Community Hospital SettingTrends in Childhood and Adolescent Cancer Survival in Sweden 1960 Through 1984Controversies in the management of non-Hodgkin lymphomaPromace-C-Mopp in Aggressive Non-Hodgkin's Lymphoma Long-Term Results in 45 Patients Treated in a Single InstitutionSuccessful pregnancy following treatment of primary malignant lymphoma of the uterine cervixHeterogeneity of immunoglobulin gene rearrangements in B-cell lymphomasMACOP-B treatment for advanced stage diffuse large cell lymphoma: A multicenter Italian studyT-Cell Phenotype Is Associated with Decreased Survival in Non-Hodgkin's LymphomaMetastatic Cancer from Unknown Primary SiteManifestations of human T-lymphotropic virus type I infectionSemantics and the Chemotherapy of Hodgkin's Disease—Resistance is Not Relapse: Alternative Chemotherapy Lacks Effectiveness for Disease Not Totally Responsive to Initial MOPP TreatmentChemotherapy in the elderlyCyclophosphamide, vincristine, adriamycin, and prednisone (CHOP) with and without intermediate dose methotrexate for the treatment of non-Hodgkin's lymphomas of diffuse histologyRadiology of the lymphomasTherapiekonzepteAdvanced Lymphoma and CHOP ChemotherapyARTURO PEREIRA, M.D., EMILIO MONTSERRAT, M.D., FRANCISCO CERVANTES, M.D., ClRIL ROZMAN, M.D.Identification of Major Prognostic Subgroups of Patients with Large-Cell Lymphoma Treated with m-BACOD or M-BACODMARGARET A. SHIPP, M.D., DAVID P. HARRINGTON, Ph.D., MARY M. KLATT, M.A., MAXINE S. JOCHELSON, M.D., GERALDINE S. PINKUS, M.D., JESSICA L. MARSHALL, B.S., DAVID S. ROSENTHAL, M.D., ARTHUR T. SKARIN, M.D., GEORGE P. CANELLOS, M.D.COPBLAM: Infusion Chemotherapy for Large Cell LymphomaBone Metastasis Prognosis, Diagnosis and Treatment 1 July 1985Volume 103, Issue 1Page: 140-142KeywordsBloodCancer chemotherapyCancer treatmentChemotherapyCombination chemotherapyLymphoma ePublished: 1 December 2008 Issue Published: 1 July 1985 PDF downloadLoading ...